Generation Bio is a genetic medicines company providing durable, redosable treatments for potentially various of patients living with rare and prevalent diseases. Co.'s non-viral genetic medicine platform incorporates its DNA construct called closed-ended DNA; its cell-targeted lipid nanoparticle delivery system; and its capsid-free manufacturing process that uses its proprietary cell-free rapid enzymatic synthesis, to produce ceDNA. Using Co.'s platform, it is developing genetic medicines to provide targeted delivery of genetic payloads that include large and multiple genes to a range of cell types across a range of diseases. The GBIO average annual return since 2020 is shown above.
The Average Annual Return on the GBIO average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether GBIO average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GBIO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|